Literature DB >> 16389891

Development of a registry for monitoring psychotropic drug prescriptions: aims, methods and implications for ordinary practice and research.

Corrado Barbui1, Michela Nosè, Gianluca Rambaldelli, Chiara Bonetto, Deborah Levi, Scott B Patten, Michele Tansella.   

Abstract

In psychiatry, individual-based registries have provided key information on risks and benefits associated with the use of psychotropic drugs but they have rarely been employed for monitoring and evaluating the everyday prescribing of psychopharmacological treatments. This article describes the cultural background that gave impetus to the idea of registering all prescriptions of psychotropic drugs dispensed by physicians working in the South Verona community mental health service, and presents the methodology employed to develop such a registry in a community psychiatric service where a psychiatric case register (PCR) has been operating since 1978. We developed a registry including every patient receiving psychotropic medications in ordinary practice. This registry is linked to the PCR in order to obtain data on social and demographic characteristics, clinical symptoms, diagnosis, use of services, and outcomes. No exclusion criteria are allowed--anyone receiving treatment is automatically included. This system, which can link drug and service-use data with hard outcome indicators, can generate information on the proportion of subjects discontinuing treatment, switching medication because of side-effects, recovery or inefficacy, as well as on the proportion of subjects failing to return to the physician, and the proportion of patients who improve. The innovative aspect of this approach is that this registry is developed, organized and used by physicians interested in monitoring their clinical practice and in providing patients, relatives and the public with accurate information on drug use in their specific context of care.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16389891      PMCID: PMC6878248          DOI: 10.1002/mpr.1

Source DB:  PubMed          Journal:  Int J Methods Psychiatr Res        ISSN: 1049-8931            Impact factor:   4.035


  22 in total

Review 1.  Design issues for drug epidemiology.

Authors:  A D McMahon; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

2.  A reevaluation of the exclusion criteria used in antidepressant efficacy trials.

Authors:  Michael A Posternak; Mark Zimmerman; Gabor I Keitner; Ivan W Miller
Journal:  Am J Psychiatry       Date:  2002-02       Impact factor: 18.112

3.  Regulatory issues in Europe.

Authors:  C Barbui; G Guaiana; S Garattini
Journal:  J Clin Psychopharmacol       Date:  2001-12       Impact factor: 3.153

4.  Pharmacoepidemiology: a scientific basis for outcomes research.

Authors:  T H Grasela
Journal:  Ann Pharmacother       Date:  1996-02       Impact factor: 3.154

5.  Antipsychotic medication adherence: is there a difference between typical and atypical agents?

Authors:  Christian R Dolder; Jonathan P Lacro; Laura B Dunn; Dilip V Jeste
Journal:  Am J Psychiatry       Date:  2002-01       Impact factor: 18.112

6.  Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?

Authors:  Mark Zimmerman; Jill I Mattia; Michael A Posternak
Journal:  Am J Psychiatry       Date:  2002-03       Impact factor: 18.112

7.  The use of a case register to evaluate the costs of psychiatric care.

Authors:  F Amaddeo; J Beecham; P Bonizzato; A Fenyo; M Knapp; M Tansella
Journal:  Acta Psychiatr Scand       Date:  1997-03       Impact factor: 6.392

8.  Cross-sectional database analysis of antidepressant prescribing in Italy.

Authors:  Corrado Barbui; Elena Broglio; Anna Costa Laia; Solangela D'Agostino; Fiorenza Enrico; Lorenza Ferraro; Emmanuela Fiorio; Flavia Miletti; Clara Pietraru; Lorena Poggio; Gianni Tognoni
Journal:  J Clin Psychopharmacol       Date:  2003-02       Impact factor: 3.153

9.  How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial?

Authors:  Gabor I Keitner; Michael A Posternak; Christine E Ryan
Journal:  J Clin Psychiatry       Date:  2003-09       Impact factor: 4.384

10.  Prescriber profile and post-marketing surveillance.

Authors:  W Inman; G Pearce
Journal:  Lancet       Date:  1993-09-11       Impact factor: 79.321

View more
  3 in total

1.  Adverse effects of antipsychotic drugs: survey of doctors' versus patients' perspective.

Authors:  Michela Nosè; Maria Angela Mazzi; Eleonora Esposito; Marco Bianchini; Paola Petrosemolo; Giovanni Ostuzzi; Michele Tansella; Corrado Barbui
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-11-28       Impact factor: 4.328

2.  Benzodiazepine use in the real world of psychiatric practice: low-dose, long-term drug taking and low rates of treatment discontinuation.

Authors:  Antonio Veronese; Massimo Garatti; Andrea Cipriani; Corrado Barbui
Journal:  Eur J Clin Pharmacol       Date:  2007-07-10       Impact factor: 2.953

Review 3.  The advantages and barriers in the implementation of a substance dependence treatment information system (SDTIS).

Authors:  Sima Ajami; Zahra Mellat-Karkevandi
Journal:  J Res Med Sci       Date:  2015-11       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.